血管内皮生长因子表达与肝癌患者临床病理特征及预后的关系研究

目的:研究肝细胞肝癌(HCC)组织中血管内皮生长因子(VEGF)表达与患者临床病理特征及预后的关系。方法:采用免疫组织化学染色法检测79例在广西医科大学附属肿瘤医院行肝癌根治性切除术的HCC患者癌组织中VEGF的表达情况,分析VEGF表达与树突状细胞(DC)浸润程度、肿瘤大小、癌栓、包膜、血清AFP水平及术后肝外转移的关系,随访患者术后生存情况及肿瘤复发情况。结果:79例HCC患者中,VEGF低表达43例(54.4%),高表达36例(45.6%)。VEGF表达与DC浸润程度、肿瘤直径及血清AFP水平有关(P0.05)。VEGF高表达组2年内复发率为83.3%(30/36),明显高于VEGF低表达组的60.5%(26/43),差异有统计学意义(P0.05)。结论:VEGF与癌组织DC浸润程度、肿瘤直径及血清AFP水平有关,其在HCC组织中高表达可能增加肝癌术后短期复发风险,可作为肝癌早期复发预警指标

疏水相互作用与亲水相互作用组合色谱纯化缩宫素

将疏水相互作用色谱与亲水相互作用色谱结合,建立了用于化学合成缩宫素粗品分离纯化的两步纯化工艺.先以纯水为流动相,采用Nylon6疏水相互作用色谱对粗品进行脱盐与富集,后以Superose12亲水相互作用色谱进行进一步纯化,两步纯化后,峰面积纯度达93.5%,提高了5.96倍,总回收率为50.1%,与用C18为介质的传统两步反相色谱纯化的结果相当.本方法有机溶剂用量仅为传统反相色谱的1/7,且两种介质都能耐受极端pH值清洗条件,重复利用率高

疏水相互作用与亲水相互作用组合色谱纯化缩宫素

将疏水相互作用色谱与亲水相互作用色谱结合,建立了用于化学合成缩宫素粗品分离纯化的两步纯化工艺.先以纯水为流动相,采用Nylon6疏水相互作用色谱对粗品进行脱盐与富集,后以Superose12亲水相互作用色谱进行进一步纯化,两步纯化后,峰面积纯度达93.5%,提高了5.96倍,总回收率为50.1%,与用C18为介质的传统两步反相色谱纯化的结果相当.本方法有机溶剂用量仅为传统反相色谱的1/7,且两种介质都能耐受极端pH值清洗条件,重复利用率高

Study of Preparation and Binding Characteristics of Molecularly Imprinted Polymers for 1-(2-Pyridylazo)-2-naphthol

以α-甲基丙烯酸为功能单体,在氯仿溶剂中,利用传统的分子印迹聚合物制备技术,成功合成了偶氮类分子1-(2-吡啶偶氮)-2-萘酚的印迹聚合物。用红外光谱、紫外光谱等技术对聚合物进行了表征测定,并用平衡结合实验研究了聚合物的吸附特性。A molecularly imprinted polymer,1-(2-pyridylazo)-2naphthol,was synthesized with α-acrylic acid as a functional monomer in the chloroform solvent by classical molecularly imprinted technique.The polymer was characterized by IR,UV spectra and the equilibrium binding experiment.The adsorption capability and adsorption kinetics of the polymer was investigated in the study.The results showed that the molecularly imprinted polymer is highly selective to 1-(2-pyridylazo)-2-naphthol.福建省教育厅科技项目(No.JA07156

疏水相互作用与亲水相互作用组合色谱纯化缩宫素

将疏水相互作用色谱与亲水相互作用色谱结合,建立了用于化学合成缩宫素粗品分离纯化的两步纯化工艺.先以纯水为流动相,采用Nylon6疏水相互作用色谱对粗品进行脱盐与富集,后以Superose12亲水相互作用色谱进行进一步纯化,两步纯化后,峰面积纯度达93.5%,提高了5.96倍,总回收率为50.1%,与用C18为介质的传统两步反相色谱纯化的结果相当.本方法有机溶剂用量仅为传统反相色谱的1/7,且两种介质都能耐受极端pH值清洗条件,重复利用率高

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Determination of the number of ψ(3686) events taken at BESIII

The number of ψ(3686) events collected by the BESIII detector during the 2021 run period is determined to be (2259.3±11.1)×106 by counting inclusive ψ(3686) hadronic events. The uncertainty is systematic and the statistical uncertainty is negligible. Meanwhile, the numbers of ψ(3686) events collected during the 2009 and 2012 run periods are updated to be (107.7±0.6)×106 and (345.4±2.6)×106, respectively. Both numbers are consistent with the previous measurements within one standard deviation. The total number of ψ(3686) events in the three data samples is (2712.4±14.3)×10^